公开(公告)号：US20200164064A1

公开(公告)日：2020-05-28

申请号：US16667464

申请日：2019-10-29

Applicant: Hoffmann-La Roche Inc.

Inventor： Joerg BENZ ,  Ulrich BRINKMANN ,  Stefan DENGL ,  Sebastian DZIADEK ,  Guy GEORGES ,  Michael GROTE ,  Alexander HAAS ,  Eike HOFFMANN

IPC: A61K39/385 ,  G01N33/68 ,  C07K16/46 ,  C07K16/00 ,  B82Y5/00 ,  C07K16/44 ,  C07K16/40 ,  C07K16/28 ,  C07K16/16 ,  A61K47/68

Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.

公开(公告)号：US20240082437A1

公开(公告)日：2024-03-14

申请号：US18271835

申请日：2022-01-10

Applicant: Hoffmann-La Roche Inc.

Inventor： Christian KLEIN ,  Alexander HAAS ,  Sabine IMHOF-JUNG ,  Sofia FROST

IPC: A61K51/10 ,  A61P35/00 ,  C07K16/30

CPC classification number: A61K51/1048 ,  A61P35/00 ,  C07K16/3007

Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target effector moieties to said cells, and to methods of using the same.

公开(公告)号：US20180282409A1

公开(公告)日：2018-10-04

申请号：US15763868

申请日：2016-09-30

Applicant: Hoffmann-La Roche Inc.

Inventor： Claudia FERRARA KOLLER ,  Guy GEORGES ,  Alexander HAAS ,  Hubert KETTENBERGER ,  Ekkehard MOESSNER ,  Tilman SCHLOTHAUER ,  Michael MOLHOJ ,  Laurent LARIVIERE

IPC: C07K16/28

Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

公开(公告)号：US20220267463A1

公开(公告)日：2022-08-25

申请号：US17625719

申请日：2020-07-10

Applicant: Hoffmann-La Roche Inc.

Inventor： Pablo UMANA ,  Sabine IMHOF-JUNG ,  Alexander HAAS ,  Christian KLEIN ,  Sofia FROST ,  Felix BORMANN ,  Guy GEORGES ,  Sebastian FENN ,  Florian LIPSMEIER ,  Daniela MATSCHEKO ,  Joerg MOELLEKEN ,  Barbara WEISER

IPC: C07K16/30 ,  C07K16/44 ,  A61K51/04 ,  A61P35/00

Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same.

公开(公告)号：US20210324108A1

公开(公告)日：2021-10-21

申请号：US16760820

申请日：2018-10-31

Applicant: Hoffmann-La Roche Inc.

Inventor： Maria AMANN ,  Claudia FERRARA KOLLER ,  Reto FLURY ,  Guy GEORGES ,  Sandra GRAU-RICHARDS ,  Alexander HAAS ,  Friederike HESSE ,  Sabine IMHOF-JUNG ,  Christian KLEIN

IPC: C07K16/40 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30

Abstract: The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20150239947A1

公开(公告)日：2015-08-27

申请号：US14706645

申请日：2015-05-07

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Ulrich BRINKMANN ,  Alexander HAAS ,  Daniela MAISEL

IPC: C07K14/47

CPC classification number: C07K14/47 ,  A61K47/6455 ,  C07K1/1075 ,  C07K1/1077 ,  C07K14/00 ,  C07K14/435

Abstract: The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles.

Abstract translation: 本发明涉及人细胞穿透肽（CPP）的鉴定和功能表征及其用途; 特别是作为转染载体。

公开(公告)号：US20230272116A1

公开(公告)日：2023-08-31

申请号：US18014729

申请日：2021-07-08

Applicant: Hoffmann-La Roche Inc.

Inventor： Alexander HAAS ,  Sabine IMHOF-JUNG ,  Christian KLEIN ,  Sofia FROST

IPC: C07K16/46 ,  A61K51/04

CPC classification number: C07K16/468 ,  A61K51/0482 ,  A61K51/0495 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/565

Abstract: The present invention relates to a set of antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same. The antibodies each comprising a Fab binding to the target antigen fused at the C-terminus of the VH to the N-terminus of the Fc and a VH or VL binding to a radiolabelled compound. The VH or VL are fused at the C-terminus to the N-terminus of the Fc. VH and VL form an antigen binding site when the antibody binds via the scFv to the target antigen.

公开(公告)号：US20220389116A1

公开(公告)日：2022-12-08

申请号：US17048073

申请日：2019-04-16

Applicant: Hoffmann-La Roche Inc.

Inventor： Christian KLEIN ,  Pablo UMANA ,  Alexander HAAS ,  Barbara WEISER ,  Florian LIPSMEIER ,  Guy GEORGES ,  Sebastian FENN ,  Joerg MOELLEKEN ,  Felix BORMANN ,  Daniela MATSCHEKO

IPC: C07K16/44 ,  C07K16/30 ,  C07K16/32 ,  C07K16/28

Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies. It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and compositions useful in such methods. The chelated radionuclides may be a DOTAM-lead (Pb) chelate.

公开(公告)号：US20220031871A1

公开(公告)日：2022-02-03

申请号：US17048072

申请日：2019-04-16

Applicant: Hoffmann-La Roche Inc. ,  Orano Med SAS

Inventor： Julien TORGUE ,  Paul JUREK ,  Federico ROJAS-QUIJANO ,  Garry E. KIEFER ,  Olivier FREYTAG ,  Christian GERDES ,  Christian KLEIN ,  Pablo UMANA ,  Alexander HAAS ,  Sofia FROST ,  Amal SAIDI ,  Tapan NAYAK

IPC: A61K51/04 ,  A61K51/06 ,  A61K51/10 ,  A61P35/00

Abstract: The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies, It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and radioimmunotherapy. It additionally relates to clearing agents and useful in such methods.

公开(公告)号：US20210403924A1

公开(公告)日：2021-12-30

申请号：US17362038

申请日：2021-06-29

Applicant: Hoffmann-La Roche Inc.

Inventor： Alexander HAAS

IPC: C12N15/65 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

Abstract: Herein is reported a method for providing cells that express a fusion protein from a marker protein and a cell-endogenous target protein, consisting of the steps a) transfecting the cells i) with a Cas9-encoding plasmid additionally containing a nucleic acid which is resistant to a first selection agent, ii) with a circular donor plasmid containing a first nucleic acid which confers resistance to a second selection reagent, and a second nucleic acid which encodes the marker protein and which is flanked 3′ and 5′ by nucleic acids homologous to the integration site in the cell, iii) a suitable synthetic crRNA, and iv) a suitable synthetic tracrRNA, b) cultivating the cells in the presence of the first and the second selection reagent, and c) selecting cells which under the conditions of step b) carry out cell division, and thereby providing/producing cells that express a fusion protein of a marker protein and a cell-endogenous target protein.